Food Stocks are Rising, and CellAg Leads the SectorRising food costs and inflation worldwide are benefiting food industry stocks as consumers are paying more for food, leading to increased profits for food companies. In addition, the food industry is considered a staple industry, providing essential products to consumers, leading to relatively stable and consistent returns for investors. Furthermore, food stocks are considered relatively recession proof given the inelasticity of demand for basic food products. As a result, food industry stocks have become increasingly attractive investments, with increased demand driving up share values prices.
Over the past month the 5 of the 6 food stocks I've got in my portfolio are showing largely positive returns, with a clear preference for food technology over more industrial-scale food, particularly meat, manufacturers. Take a look at the spread; whereas SPY, a convenient baseline, is +6.6% since 12/30. Underperforming this was JBSS, with a performance near par. One factor contributing to this was political instability in Brazil, which has exerted a bearish effect on multinationals like JBS based in the country.
TSN and BHIL, two US meat mainstays, performed +7.67% and +18.89%, respectively. Nice gains over a short window indeed. However, they've been left ion the dust by food tech companies with exposure to the CellAg market.
Take KROP, a foodtech ETF. It has broad exposure to a range of food-related securities including CellAg, and its +19.73% over the last month. This leaves its 1mo performance suspended between the big meat stocks and more speculative cultivated meat plays.
And that takes us to the other end of the spectrum; following some volatility associated with a recent share offering, STKH is +35.71%, a clear lead for my portfolio. Performance has been more moderate for LSE's ANIC (+14.41%) and CULT (+17%).
Overall, Q1 '23 is shaping up to be a very strong Q for food stocks and consumer defensives as a whole. While I'm planning on holding biggies like TSN, JBS, and BHIL on a LT horizon, STKH and other cultivated meat stocks are looking increasingly bullish as the field moves forward by leaps and bounds.
Foodtech
UPSID 'Food's FDA Approval Drives CellAg GainsFor food tech watchers and enthusiasts, November has proven a momentous month. On November 16th, the FDA completed its first pre-market consultant with Upside Foods to determine the safety of their cultivated meat products for American consumers. Significantly, the FDA gave Upside a green light to continue R&D, tacitly signaling that the world's most influential regulatory body takes no issues with food safety concerns vis-a-vis cultured meat products. Though this is not FDA approval, its a strong testament to federal regulators' increasingly receptive stance towards cellular agriculture as a sustainable meat alternative.
Despite notable levels of background volatility as markets rallied around Black Friday and the Thanksgiving holiday season, the impact of the FDA green light was bullish to neutral on relevant actors. Using S&P500 as a rough baseline (+2% since Nov 16), we observe immediate price action movements in response to the announcement. Steakholder Foods (NASDAQ: STKH), a cultured meat pure-play, registered nearly 30% gains in three days following the news. STKH hails from Israel and was the first cultured meat listee on NASDAQ; its strong bullish response to the Upside Foods breakthrough is sensible, given its exclusive focus on the development of tech needed to scale and catalyze broader adoption of cellAg products. That said, over the last two weeks STKH underwent a correction and is currently outperforming the SPY by a slight 1.25% margin since Nov 16.
Somewhat unintuitively, Cult Food Science (CSE: CULT) reacted bearishly to the news, first witnessing double-digit SP dips after which CULT popped on the heels of an announcement about a major European distribution deal for an affiliate that specializes in bee-free honey. That said, CULT has been subject to what looks like serious manipulation since its Q1 '22 IPO and its SP has seen a fair share of wild swings.
Both Agronomics Limited (LSE: ANIC), a investment firm heavily staked in food tech and cellAg, and Tysons (NYSE: TSN) displayed little direct price action movement in response to the Upside Foods announcement. To me, this checks out given that 1) ANIC is a British-listed investment platform and thus more immune to catalyst-driven sectoral swings, and 2) TSN's is one of the US' big four meat producers. Though they have directed significant capital to cultivated meat R&D, they remain first and foremost a mainstream food giant. I would not have been surprised if TSN stock had reacted negatively given its vested interest in traditional slaughtered meet, but in the end TSN closely tracked SPY in the immediate aftermath of the NR.
To tie things up, the Upside Food FDA greenlight is a major catalyst for cellAg players worldwide. It exerted a directly bullish impact of STKH SP, which jumped nearly 30% in response. Other relevant tickers were slower to respond, indicative of either skewing variables or macro dynamics. This is just a first step, once we see proper FDA approval I am of the firm opinion that currently undervalued foodtech companies will see in windfall of investor demand.